Asco 2021 – Guardant shoots for the moon
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
Focus on Covid-19 does not distract the FDA
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Exact gatecrashes the liquid biopsy party
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
With its liquid biopsy approval, Foundation Medicine takes on Guardant
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
